In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously ... measured when we define obesity according to body mass index is not the aspect of overweight that is relevant ...

In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously studied detergent ... suggesting that what is measured when we define obesity according to body mass index is not the ...

Novo Nordisk (NVO) announced that the Food and ... along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

The glycemic index is a measure used to determine how much a food can affect your blood sugar levels. Several factors affect the glycemic index of a food, including the ripeness, nutrient ...

I’m cautious about Novo Nordisk's stock in the short term due ... and cagrilintide (amylin analog), targeting weight loss and glycemic control. Phase 2 trial was completed in August 2022 ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...